STEM CELLS FOR BIOLOGICAL ASSAYS OF NOVEL DRUGS AND PREDICTIVE TOXICOLOGY
StemBANCC aims to provide well characterised patient derived induced pluripotent stem cell lines and associated biomaterials in an accessible and sustainable bio-bank. StemBANCC also aims to demonstrate proof of concept for the utility of induced pluripotent stem cells in drug discovery for hard-to-treat disorders.
Currently, many drugs fail relatively late in the drug development process because the tests used in the earlier stages of drug development simply do not reflect what happens in real life when the drug is administered in patients. This is partly because these early tests rely heavily on animal cells, and when human cells are used, they have often been extensively modified to survive in culture and so no longer behave naturally. Those working in drug research and development therefore urgently need a well-characterized and renewable supply of cells that more accurately mimic what happens in the human body.
The main aim of the StemBANCC project is to generate and characterise high quality human induced pluripotent stem (iPS) cell lines from 500 subjects that can be used by researchers to study a range of diseases, including diabetes and dementia, and test for drug efficacy and safety. The cell lines will help to improve and speed up the drug development process, and ensure that patients benefit from more effective and safer drugs.